Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Axsome Thera (AXSM)

Axsome Thera (AXSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,525,079
  • Shares Outstanding, K 37,570
  • Annual Sales, $ 0 K
  • Annual Income, $ -102,900 K
  • 60-Month Beta 2.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 25.90
Trade AXSM with:

Options Overview

Details
  • Implied Volatility 63.17%
  • Historical Volatility 47.74%
  • IV Percentile 10%
  • IV Rank 23.97%
  • IV High 98.34% on 04/23/21
  • IV Low 52.08% on 01/20/21
  • Put/Call Vol Ratio 0.28
  • Today's Volume 1,620
  • Volume Avg (30-Day) 707
  • Put/Call OI Ratio 1.82
  • Today's Open Interest 32,768
  • Open Int (30-Day) 31,782

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.88
  • Number of Estimates 7
  • High Estimate -0.77
  • Low Estimate -0.99
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -79.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.36 +20.71%
on 05/25/21
69.56 -5.66%
on 06/15/21
+7.20 (+12.32%)
since 05/14/21
3-Month
50.05 +31.11%
on 04/21/21
69.56 -5.66%
on 06/15/21
-0.13 (-0.20%)
since 03/16/21
52-Week
50.05 +31.11%
on 04/21/21
90.00 -27.09%
on 09/14/20
-10.93 (-14.28%)
since 06/16/20

Most Recent Stories

More News
Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.

RGEN : 190.14 (+0.26%)
ADPT : 37.96 (-1.09%)
AXSM : 65.62 (-2.37%)
BNTX : 203.85 (-6.56%)
Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia

Submission anticipated in 4Q 2022

AXSM : 65.62 (-2.37%)
Why Is Axsome (AXSM) Up 14.7% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AXSM : 65.62 (-2.37%)
US Pain Relief Therapeutics Market Share 2021 : Growth Opportunities with Covid-19 Impact Analysis, Business Structure with Top Key Players Size, Development Plans and Challenges Forecast to 2027

The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...

ABT : 110.06 (-0.32%)
ACRX : 1.3700 (-1.44%)
ACOR : 4.10 (-1.91%)
AXSM : 65.62 (-2.37%)
BAYRY : 16.0600 (-1.44%)
BDRFF : 124.8000 (+4.57%)
BDSI : 3.56 (-0.28%)
BMY : 66.92 (-0.74%)
COLL : 22.70 (-1.09%)
DEPO : 7.30 (+1.67%)
DRRX : 1.7200 (+3.61%)
EGLT : 0.0315 (-63.37%)
LLY : 220.76 (-1.23%)
FLXN : 9.20 (-2.85%)
GLPG : 76.25 (-1.73%)
HRTX : 15.75 (+1.81%)
KMPH : 15.03 (+0.20%)
MRK : 76.61 (+1.20%)
MESO : 8.17 (-0.73%)
NKTR : 17.36 (-2.20%)
NVS : 93.79 (-0.13%)
ORXOY : 4.8600 (-11.60%)
PFE : 39.30 (-0.73%)
REGN : 523.58 (-0.74%)
VRX.TO : 30.80 (-3.33%)
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus

Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.

RGEN : 190.14 (+0.26%)
ADPT : 37.96 (-1.09%)
AXSM : 65.62 (-2.37%)
BNTX : 203.85 (-6.56%)
Axsome: Q1 Earnings Snapshot

NEW YORK (AP) _ Axsome Therapeutics Inc. (AXSM) on Monday reported a loss of $29.3 million in its first quarter.

AXSM : 65.62 (-2.37%)
Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern

AXSM : 65.62 (-2.37%)
Axsome Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 10, 2021 / Axsome Therapeutics, Inc. (NASDAQ:AXSM) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 8:00...

AXSM : 65.62 (-2.37%)
Why Earnings Season Could Be Great for Axsome Therapeutics (AXSM)

Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

AXSM : 65.62 (-2.37%)
Axsome Therapeutics Joins Mental Health America and other Advocacy Organizations in Raising Awareness and Providing Support for Mental Health During Mental Health Month

Axsome Therapeutics, Inc. (NASDAQ: AXSM) is joining Mental Health America (MHA) and other advocacy organizations in observing May is Mental Health Month, by raising awareness of and supporting people living...

AXSM : 65.62 (-2.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc....

See More

Key Turning Points

3rd Resistance Point 72.28
2nd Resistance Point 70.15
1st Resistance Point 67.88
Last Price 65.62
1st Support Level 63.48
2nd Support Level 61.35
3rd Support Level 59.08

See More

52-Week High 90.00
Fibonacci 61.8% 74.74
Fibonacci 50% 70.03
Last Price 65.62
Fibonacci 38.2% 65.31
52-Week Low 50.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar